IRCT20140818018842N26招募中1 期
Rituximab and Allogeneic Natural Killer Cells for Refractory Lymphoid Malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Age 18 years or older
- •adequate organ function at the time of infusion
- •After the failure of at least 2 prior lines of therapy
- •Histologically confirmed malignant lymphoma
- •Adequate performance score: KPS >70 or ECOG 0-2
排除标准
- •CNS lymphoma
- •HIV patients
- •Patients with a history of autoimmune disease
研究者
相似试验
已完成
1 期
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell TransplantationTransplantation, Stem CellLymphoid MalignanciesDisorder Related to TransplantationLymphomaLeukemiaNCT00383994M.D. Anderson Cancer Center6
尚未招募
不适用
Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib for the treatment of relapsed or refractory primary central nervous system lymphomaKCT0008105Chonnam National University Hospital Hwasun Hospital29
已完成
2 期
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid MalignanciesNon-Hodgkin LymphomaChronic Lymphocytic LeukemiaNCT01181258Masonic Cancer Center, University of Minnesota16
进行中（未招募）
1 期
Phase II study. A combination of Lenalidomide and Rituximab as front line therapy for elderly frail patients (CGA) with Diffuse Large B-cells non-Hodgkin Lymphoma.Diffuse Large B-cells non-Hodgkin LymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-003371-29-ITFONDAZIONE ITALIANA LINFOMI ONLUS68
终止
2 期
Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaLymphoma, B-CellNCT00216164Hoosier Cancer Research Network8